CRISPR Therapeutics (CRSP) Options Chain & Prices $54.92 +0.94 (+1.74%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$54.52 -0.40 (-0.72%) As of 06/26/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Options Chain Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRSP Put and Call Options List 1/21/2028 1/15/2027 10/16/2026 9/18/2026 8/21/2026 8/7/2026 7/31/2026 7/24/2026 7/17/2026 7/10/2026 7/2/2026 Options Date Put and Call Options Put Options Call Options Options Type All In The Money Out of The Money Moneyness With Volume Without Volume All Volume Strike Price Min Strike Price Max Export ExpiresStrike PriceClose PricePut/CallVolumeVolume AskVolume BidOpen InterestImplied VolatilityDeltaTrades7/2/2026$45.00$0.090Put3210922(+0)88.87% (+2.92%)-0.03564257/2/2026$46.00$9.097Call1 - - 6(+0)84.70% (+2.78%)0.95494617/2/2026$47.00$0.149Put3 - - 24(+1)80.52% (+2.51%)-0.06006737/2/2026$47.50$0.170Put21 - 11(+0)78.54% (+2.41%)-0.06861327/2/2026$49.00$6.211Call1 - - 11(+0)72.82% (+2.06%)0.89812917/2/2026$50.00$0.345Put3241537(+11)69.26% (+1.74%)-0.136256117/2/2026$51.00$0.464Put10713(+1)66.07% (+1.43%)-0.17886277/2/2026$52.00$0.640Put12 - 1112(+2)63.09% (+0.82%)-0.23788637/2/2026$52.00$3.593Call27 - - 22(-1)63.09% (+0.82%)0.764787/2/2026$53.00$0.884Put102122(+2)60.72% (+0.17%)-0.3108115 Get the Latest News and Ratings for CRSP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/2/2026$53.00$2.836Call29 - 16(+0)60.72% (+0.17%)0.69264877/2/2026$54.00$1.222Put302 - 9(+3)59.03% (-0.57%)-0.3979277/2/2026$54.00$2.170Call361268(+0)59.03% (-0.57%)0.606561227/2/2026$55.00$1.657Put147220(+8)58.16% (-1.32%)-0.490954107/2/2026$55.00$1.617Call1154593(+15)58.15% (-1.33%)0.511613167/2/2026$56.00$2.224Put121 - 12116(+2)58.10% (-2.04%)-0.587156327/2/2026$56.00$1.183Call45716483(+455)58.12% (-2.02%)0.416529237/2/2026$57.00$0.860Call61727191(+107)58.87% (-2.57%)0.330074197/2/2026$58.00$0.635Call38819116(+55)60.21% (-3.02%)0.259592157/2/2026$59.00$0.465Call8966328(+3)62.11% (-3.23%)0.19978127/2/2026$60.00$5.431Put4 - 21(+0)64.27% (-3.40%)-0.85269847/2/2026$60.00$0.349Call561435276(+94)64.27% (-3.40%)0.155321207/2/2026$61.00$0.267Call4 - 321(+1)66.63% (-3.50%)0.12154837/2/2026$62.00$0.209Call42 - 14(+4)69.01% (-3.65%)0.09673637/2/2026$63.00$8.258Put1 - 12(+0)71.62% (-3.59%)-0.93053817/2/2026$64.00$0.131Call1 - - 121(+0)74.17% (-3.60%)0.06162817/2/2026$65.00$0.107Call4 - 323(+0)76.63% (-3.69%)0.0504954End-of-day options data provided by Trade Alert and Intrinio. Related Companies and Tools Related Companies Allogene Therapeutics Options Data Axsome Therapeutics Options Data Beam Therapeutics Options Data Editas Medicine Options Data Moderna Options Data Intellia Therapeutics Options Data Vertex Pharmaceuticals Options Data Viatris Options Data Genmab A/S Options Data Ascendis Pharma A/S Options Data Options Chain Tools Short Interest TrackerShort Interest IncreasesShort Interest DecreasesUnusual Call VolumeUnusual Put Volume This page (NASDAQ:CRSP) was last updated on 6/27/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredSpaceX is offering you shares. Don't take them.SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...Behind the Markets | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
